YU227379A - Process for obtaining (r,r) optical labetalol - Google Patents

Process for obtaining (r,r) optical labetalol

Info

Publication number
YU227379A
YU227379A YU02273/79A YU227379A YU227379A YU 227379 A YU227379 A YU 227379A YU 02273/79 A YU02273/79 A YU 02273/79A YU 227379 A YU227379 A YU 227379A YU 227379 A YU227379 A YU 227379A
Authority
YU
Yugoslavia
Prior art keywords
labetalol
acid addition
optical
optical isomer
protected
Prior art date
Application number
YU02273/79A
Other languages
English (en)
Inventor
E H Gold
W Chang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of YU227379A publication Critical patent/YU227379A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epoxy Compounds (AREA)
YU02273/79A 1978-09-20 1979-09-18 Process for obtaining (r,r) optical labetalol YU227379A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94451678A 1978-09-20 1978-09-20

Publications (1)

Publication Number Publication Date
YU227379A true YU227379A (en) 1983-06-30

Family

ID=25481553

Family Applications (1)

Application Number Title Priority Date Filing Date
YU02273/79A YU227379A (en) 1978-09-20 1979-09-18 Process for obtaining (r,r) optical labetalol

Country Status (27)

Country Link
EP (1) EP0009702B1 (enExample)
JP (3) JPS5555147A (enExample)
KR (2) KR830000904A (enExample)
AT (1) ATE351T1 (enExample)
AU (1) AU528626B2 (enExample)
CA (1) CA1151211A (enExample)
CY (1) CY1175A (enExample)
DD (1) DD150457A5 (enExample)
DE (1) DE2961263D1 (enExample)
DK (1) DK387579A (enExample)
FI (1) FI792884A7 (enExample)
GR (1) GR73179B (enExample)
HK (1) HK13383A (enExample)
HU (1) HU185523B (enExample)
IE (1) IE49301B1 (enExample)
IL (1) IL58258A (enExample)
KE (1) KE3283A (enExample)
MY (1) MY8500042A (enExample)
NO (1) NO149660C (enExample)
NZ (1) NZ191589A (enExample)
OA (1) OA06339A (enExample)
PH (1) PH16794A (enExample)
PL (1) PL129114B1 (enExample)
PT (1) PT70191A (enExample)
SG (1) SG283G (enExample)
YU (1) YU227379A (enExample)
ZA (1) ZA794872B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
IT1194406B (it) * 1983-09-27 1988-09-22 Scharper S P A Procedimento per la preparazione di 2-idrossi-5-01-idrossi-2-((4-fenil-2-butil)ammino) etil benzammide
HU190867B (en) * 1984-01-20 1986-11-28 Egyt Gyogyszervegyeszeti Gyar,Hu Process for preparing 2-hydroxy-5-/1-hydroxy-2-/1-methyl-3-phenyl-propyl/-amino/ethyl/-benzamide and pharmaceutically acceptable salts thereof
US4788183A (en) * 1987-11-30 1988-11-29 Schering Corporation Method for treatment of dyslipidemia in humans
US4879233A (en) * 1989-02-10 1989-11-07 Schering Corporation Novel Aspergillus niveus microorganism used for the chiral reduction of carbonyl groups
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DE69233586T2 (de) * 1991-08-23 2006-09-28 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-Rezeptor aktive Verbindungen
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
JP4117506B2 (ja) * 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド 無機イオン活性化合物
IT1313583B1 (it) * 1999-07-30 2002-09-09 Chiesi Farma Spa Derivati 2-amminotetralinici per la terapia del glaucoma.
EP1961735B1 (en) * 2007-02-22 2009-11-18 Indena S.P.A. Process for the preparation of (2r,3s)-3-phenylisoserine methyl ester acetate salt
JP6245983B2 (ja) 2010-08-11 2017-12-13 ドレクセル ユニバーシティ パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
AU2015346371A1 (en) * 2014-11-11 2017-04-27 Western University Of Health Sciences Isoform-specific calpain inhibitors, methods of identification, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1266058A (enExample) * 1969-07-08 1972-03-08
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
GB1541932A (en) * 1975-04-17 1979-03-14 Scherico Ltd Diastereoisomers of a phenylalkylaminoethanol derivative

Also Published As

Publication number Publication date
IL58258A (en) 1984-01-31
IE791770L (en) 1980-03-20
ZA794872B (en) 1980-11-26
SG283G (en) 1983-09-16
EP0009702A1 (en) 1980-04-16
JPH0210128B2 (enExample) 1990-03-06
KR830000904A (ko) 1983-04-28
HU185523B (en) 1985-02-28
NO792993L (no) 1980-03-21
FI792884A7 (fi) 1981-01-01
IE49301B1 (en) 1985-09-18
PL129114B1 (en) 1984-03-31
NZ191589A (en) 1984-03-30
GR73179B (enExample) 1984-02-14
HK13383A (en) 1983-04-29
OA06339A (fr) 1981-06-30
ATE351T1 (de) 1981-11-15
AU5088179A (en) 1980-03-27
JPS59108749A (ja) 1984-06-23
PL218408A1 (enExample) 1980-09-08
NO149660C (no) 1984-05-30
NO149660B (no) 1984-02-20
DD150457A5 (de) 1981-09-02
IL58258A0 (en) 1979-12-30
DE2961263D1 (en) 1982-01-14
EP0009702B1 (en) 1981-11-04
PT70191A (en) 1979-10-01
CY1175A (en) 1983-06-10
DK387579A (da) 1980-03-21
KR840005307A (ko) 1984-11-05
KR890001998B1 (ko) 1989-06-07
JPS5555147A (en) 1980-04-22
PH16794A (en) 1984-02-28
KE3283A (en) 1983-05-13
JPH02167253A (ja) 1990-06-27
AU528626B2 (en) 1983-05-05
CA1151211A (en) 1983-08-02
MY8500042A (en) 1985-12-31

Similar Documents

Publication Publication Date Title
AU528626B2 (en) Phenylalkylaminoethylsalicylamides
AU5884194A (en) Aminoacid derivates, medicaments containing these compounds and process for preparing the same
CA2029787A1 (en) Method for preparation of taxol using an oxazinone
DE69020458D1 (de) Transdermale in zwei Phasen wirkende Ausgabevorrichtung für Medikamente.
SG120493G (en) N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof
GB1459571A (en) Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
NZ236034A (en) Pharmaceutical compositions containing imidazole derivatives; topical compositions for treating glaucoma
PT90022A (pt) Processo para a preparacao de derivados cefem e dos intermediarios correspondentes
AU2347088A (en) Polyamine derivatives as antineoplastic agents
PL326554A1 (en) Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase
ES465606A1 (es) Procedimiento de preparacion de nuevos derivados de hexahi- dro-1,2,3,3a,4,5-cantina.
NO164021C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktiv (r,s)-5-amino-hepta-5,6-diensyre, (s)-4-aminohepta-5,6-diensyre og farmasoeytisk akseptable salter derav.
WO1990003172A3 (en) Bile acids for treatment of viral infections
HK17880A (en) N-(1'-allyl-2'-pyrrolidylmethyl)-2,3-dimethoxy-5-sulphamoylbenzamide and derivatives
ES524375A0 (es) Un procedimiento para preparar un compuesto de nitrato piridilalquilico
IL69448A (en) Process for combating phytopathogenic fungi with azolylphenoxy-tetrahydrofuran-2-ylidene methane derivatives
ES476078A1 (es) Un procedimiento para preparar derivados del acido 1,3-tia- zol-glioxilico.
JPS5598158A (en) Novel alpha-methyl-3,4-dihydroxyphenylalanine derivative and its preparation
JPS5753496A (en) 1-n-acyl derivative of 5,3',4'-trideoxykanamycin b or 5,3',4',6'- tetradeoxykanamycin b, and their preparation
JPS5390274A (en) Morpholine derivs., their acid salts and process for their preparation
ES8401033A1 (es) Procedimiento de obtencion de sales motoxicas de las 6-ciclohexil-1-hidroxi-4-metil 2-(1h) piridina.
ES440175A2 (es) Un procedimiento de preparacion de nuevas sales de monoeste-res de piridoxina.
ES454227A1 (es) Procedimiento para la preparacion de uretanos aromaticos.
JPS5246047A (en) Process for preparation of novel aminocyclitol derivatives
JPS5371083A (en) Optical active homophthalimide derivs. and process for their preparing them